Tralokinumab

Tralokinumab
	Tralokinumab Fab fragment bound to IL-13. From PDB 5L6Y.
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	IL-13
Clinical data
Pronunciation	/ˌtreɪləˈkɪnjʊmæb/; TRAY-lə-KIN-yuu-mab
Trade names	Adtralza, Adbry
Other names	CAT-354, tralokinumab-ldrm
License data	US DailyMed: Tralokinumab;
Routes of; administration	Subcutaneous
ATC code	D11AH07 (WHO) ;
Legal status
Legal status	CA: ℞-only / Schedule D; UK: POM (Prescription only); US: ℞-only; EU: Rx-only; Rx-only;
Identifiers
CAS Number	1044515-88-9 ;
DrugBank	DB12169 ;
ChemSpider	none;
UNII	GK1LYB375A;
KEGG	D09979;
Chemical and physical data
Formula	C6374H9822N1698O2014S44
Molar mass	143875.20 g·mol−1
	(what is this?) (verify)

Tralokinumab sold under the brand names Adtralza (EU/UK) and Adbry (US) among others, is a human monoclonal antibody used for the treatment of atopic dermatitis. Tralokinumab targets the cytokine interleukin 13.

The most common side effects include upper respiratory tract infections (colds and other infections of the nose and throat), reactions at the injection site, and redness and discomfort in the eye.

Tralokinumab was approved for medical use in the European Union and in the United Kingdom in June 2021. It was approved for medical use in the United States in December 2021. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.